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Abstract 
Health related quality of life (HRQoL) is negatively impacted in patients suffering from Parkinson’s 
disease (PD). For the specific components that comprise HRQoL, the relationship between clinical 
variables such as disease duration is not fully characterized.  In this cross-sectional study (n=302), self-
reported HRQoL on the Parkinson’s disease questionnaire (PDQ-39) was evaluated as a global construct 
as well as individual subscale scores. HRQoL was compared in three groups: those within 5 years of 
diagnosis, those within 6-10 years of diagnosis, and those greater than 11 years since diagnosis.  Non-
parametric analyses revealed lower HRQoL with increasing disease duration when assessed as a global 
construct.  However, when subscales were evaluated, difficulties with bodily discomfort and cognitive 
complaints were comparable in individuals in the 1-5 years and 5-10 year duration groups. Exploratory 
regression analyses suggested disease duration does explain unique variance in some subscales, even after 
controlling for H&Y stage and neuropsychiatric features.  Our findings show that HRQoL domains in PD 
patients are affected differentially across the duration of the disease. Clinicians and researchers may need 
to tailor interventions intended to improve HRQoL at different domains as the disease progresses.  
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Introduction 
Health related quality of life (HRQoL) in Parkinson's disease (PD) is a multifaceted construct, 
encompassing the emotional, physical, and social impacts of the condition 
1
.  In recent years, HRQoL has 
emerged as an increasingly important outcome measure for evaluating the efficacy of interventions in PD
2 
.  Studies of HRQoL in PD have revealed strong associations with several features beyond the core motor 
symptoms, including depression
3
 , fatigue,
4
 and other non-motor symptoms 
5
.  Given that PD is 
progressive with increasing motor and non-motor symptoms over time 
6
, it stands to reason that disease 
duration might be strongly correlated with HRQoL. However, some studies have found little relationship 
between disease duration and HRQoL 
7
 or found that the relationship attenuates after accounting for other 
demographic or clinical factors 
8
. According to a recent systematic review 
3
, of 20 studies examining 
factors influencing HRQoL, disease duration was retained as a significant predictor in only six.  
One potential explanation for these discrepant findings is that the association between disease 
duration and HRQoL might be more complex than a simple direct linear relationship. For example Soh 
9
 
proposed that disease duration contributes to HRQoL via its impact on motor, non-motor, mental, and 
self-care limitations.  However, the fit indices of their structural equation models were not fully desirable. 
In a similar vein, Visser and colleagues 
10
 found that depression and psychological functioning continue 
to influence HRQoL throughout the course of the disease, while pain and impaired activities of daily 
living (ADL) are only predictors of HRQoL in the early, but not in the later stages of PD.  
In addition to a more complex relationship between disease duration and HRQoL, it is also 
important to point out that the above studies often treated HRQoL as a unitary construct, by using a 
summary score in their analysis.  Because multiple domains of daily life define HRQoL, summary scores 
alone may miss more focused impacts of the disease on a particular facet of daily existence. This assertion 
is supported by previous factor analytic studies that suggest multiple components of HRQoL exist which 
overlap, but also explain a unique portion of the variance in the global construct
11
.  These individual 
facets of HRQoL may be differentially impacted by disease duration.  As an example, a 12-month study 
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of patients with PD found that the Parkinson’s Disease Questionnaire (PDQ-39) subscales of stigma, 
communication and body pain alone changed over the study course, while other subscale scores remained 
unchanged 
12
.  In another study, when comparing subscales of treated vs. untreated early stage PD patients 
over 18 months 
13
, 6 of the 8 subscales of the PDQ-39 improved with treatment over the course of 18 
months, while all domains declined in the non-treated early PD group.  Interestingly, in the treatment 
group it was mobility and ADL scores that did not change, and the magnitude of decline in the control 
group was not uniform between domains. 
In light of these findings, the current study seeks to evaluate differences in HRQoL at the 
subscale level in a cross sectional study of PD clinical outpatients.  Specifically, we sought to evaluate 
any difference in PDQ-39 subscales across patient groups in the early (0-5 years), middle (6-10 years) and 
later (11+ years) periods of disease duration.  Preliminary analyses to establish any independent 
relationship with disease duration and domains of HRQOL are also undertaken. 
Methods 
Participants and Data Acquisition 
All patients with a diagnosis of idiopathic PD in the Plummer Movement Disorders Center of 
Baylor Scott & White Hospital were asked to complete yearly surveys that include the PDQ-39 as well as 
various demographic and clinical factors. Pertinent to this survey, individuals were also asked to select 
their disease duration from several different options: 0-5 years, 6-10 years, 11-15 years, and 15+ years. 
Given small sample sizes in some of the advanced groups, these were combined into 0-5, 6-10, and 11+  
years duration for this study.  
The current study retrospectively evaluated the data collected in 2012 with the approval of Baylor 
Scott & White Hospital’s Institutional Review Board. Of the 337 surveys collected in 2012, 35 were 
incomplete and eliminated from the statistical analysis. For the remaining 302 patients, demographics, 
disease duration and HRQoL data (measured by PDQ-39) were extracted.  On the demographic 
questionnaire, items such as age were asked in terms of ranges rather than ratio level data. In addition, 
Hoehn & Yahr (H&Y 
14
) ratings or the information necessary to obtain the H&Y score was abstracted 
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from neurology notes and coded by a trained research coordinator. Demographic and clinical variables are 
found in table 1. 
 
Instruments 
The PDQ-39 
11
 is a 39-item questionnaire in which the frequency of PD-related interference on a 
number of activities, situations, and symptoms is rated using a 0 (never) to 4 (always) scale. The items are 
grouped in 8 domains: mobility, activities of daily living (ADL), emotional well-being, stigma, social 
support, cognition, communication, and bodily discomfort. Each subscale's scores are transformed into a 
0–100 scale by summing the items' raw scores, divided by the maximum possible raw score, and then 
multiplying by 100 (higher scores mean poorer HRQoL). A Summary Index (SI) is also calculated from 
the mean of the eight domain scores.   
In addition to the PDQ-39, patient’s provided relevant clinical and demographic data in a multiple 
choice format in an accompanying questionnaire.  Pertinent to the current study, patients were asked to 
endorse whether they were experiencing depression, anxiety, or thinking problems.  This information was 
also utilized in the analyses below and is summarized in Table 1. 
Data analysis 
All statistical analyses were completed in Stata 13 
15
.  Demographic and clinical variables were 
compared between groups with chi-square tests. Initial analysis of the PDQ-39 variables revealed 
significantly non-normal distributions. As such, Kruskal Wallis tests (a non-parametric variant of the 
analysis of variance) were used to compare the groups on the subscales and summary index of the PDQ-
39.  Given the multiple comparisons, Bonferonni correction on the omnibus tests was used, with a 
significance level for each analysis set to p<=0.006 for all analyses.  For significant findings, Dunn’s test 
was employed as post-hoc analyses between the three duration groups
16
. To help determine the potential 
impact of disease stage and neuropsychiatric covariates on these analyses, exploratory multiple 
regressions were conducted to evaluate the impact of these variables on HRQOL domains.   
Results 
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As would be expected, there was an increasing proportion of higher HY score with increasing 
disease duration (χ2= 44.46, p<.0001) though age difference was not significant (χ2= 7.21, p>.8).  
However, the duration groups did not differ significantly in terms of frequency of endorsed depression 
(χ2= 3.64, p>.15), anxiety (χ2= .40, p>.8) or cognitive problems (χ2= .09, p>.95).   
Kruskal Wallis test revealed a significant group effect (duration of PD) on each of the aspects of 
HRQoL as well as the summary score, with the exception of Social Support (H = 5.95, df (2), p = .05).  
According to the post-hoc analysis, the PDQ-39 Summary Index increased with increasing disease 
duration (H = 29.43, df(2), p < .001). The domains mobility (H = 22.07, df(2), p < .001), activities of 
daily living  (H = 30.02, df(2), p < .001), emotional well-being (H = 16.53, df(2), p < .001), stigma (H = 
28.50, df(2), < .001), and communication (H = 23.93, df(2), p < .001) showed a pattern where individuals 
in the 6-10 and the 11+ years disease duration groups did not differ significantly, while patients in the 0-5 
years disease duration range had significantly lower scores than both of them. On the other hand, with 
regards to cognition (H = 12.79, df(2), p = .002), and bodily discomfort (H = 10.38, df(2), p = .005), 
individuals in the 0-5 and 6-10 years of disease duration showed similar quality of life scores, which were 
significantly lower than those  reported by individuals with longer (11+ years) disease duration. This can 
be seen graphically in Figure 1.  Table 2 displays the means and standard deviations of all PDQ-39 
domains for all three disease duration groups and the results of the post-hoc analyses.  
Given the multicollinearity between disease duration and severity as well as the non-normal 
distributions of the variables, the results of multiple regression analyses must be considered only 
cautiously given the increased likelihood for increased standard error for beta weights, reduction in the 
size of the multiple correlation measures, and reduced confidence in understanding of the relative 
importance of predictors 
17
. With these caveats in mind, Table 3 demonstrates statistically significant 
variance explained by disease duration in several domains, even after accounting for H&Y stage or self-
reported depression, anxiety, or cognitive difficulties.  The strongest relationships were observed for 
activities of daily living (ADL), stigma, and communication domains.  Smaller but still statistically 
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significant additions to the explained variance were seen in mobility, emotional well being, and cognition.  
PD duration did not contribute significantly to predicting bodily discomfort and social support. 
Discussion 
Decline in HRQoL is a major concern in those with neurodegenerative disorders. In Parkinson’s 
disease, clinicians aim to improve the HRQoL in their patients via symptomatic therapies as well as 
psychosocial and other interventions.  However, just as interventions to improve HRQoL are 
multifaceted, so too is the construct itself.  While HRQoL measures are frequently condensed to a single 
summary score, the construct encompasses several domains that in turn may be differentially impacted by 
various disease-related, personal, or environmental factors. The current research clearly demonstrates this 
complexity.  As measured by the PDQ-39, HRQoL as a whole was lower in individuals of longer disease 
duration in a predictable fashion.  However, this decline was not uniform across subscales, as cognitive 
complaints and bodily discomfort were elevated and similar to one another in the 0-5 and 6-10 year 
groups. This does not mean that cognitive difficulties and bodily discomfort would be insignificant 
problems for individuals early on in the disease. On the contrary, these domains had some of the highest 
mean scores from all domains at 0-5 years of disease duration, indicating that the negative effects of 
cognitive and bodily discomfort symptoms on everyday life are seen in individuals of short disease 
duration.  
In concurrence with the results of Chapuis, Ouchchane, Metz, Gerbaud and Durif 
18
, we found 
significant difference in quality of life with increasing disease duration in mobility, activities of daily 
living, stigma and communication; however contrary to their results we did not find a significant 
difference between duration groups in the domain of social support, and the difference between disease 
duration groups was significant for the cognition and bodily discomfort domains in our study. The 
discrepancy in the results might be in part due to the smaller sample size in the study of Chapuis and 
colleagues or the fact that they treated disease duration as a continuous variable. The overall disease 
duration in their sample was also greater.  
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The question remains as to whether disease duration contributes any unique variance to 
understanding HRQoL after controlling for other predictors such as neuropsychiatric variables and overall 
disease.  Our retrospective dataset cannot answer this question definitively, and psychometric limitations 
of the data (significant non-normality) and assessment methods (i.e. single item self-reported measures 
for depression, anxiety, and cognitive impairment) make interpretation of our regression results tentative.  
However, our results would suggest that duration does make small and unique contributions to the 
variance in HRQoL, particularly for activities of daily living, stigma, and communication over and above 
disease duration.  
Given these findings, researchers utilizing HRQoL as an endpoint should consider features such 
as disease duration and individual subscale scores when interpreting results.  Studies could focus on 
evaluating specific aspects of HRQoL at different disease stages.  In addition, controlling for the impact 
of disease duration when gauging the effectiveness of an intervention on HRQoL will be important to 
avoid confounding results. 
For multi-disciplinary clinics following individuals over time, these results may help to provide 
more tailored care across the disease course. For example our findings suggest that targeting cognitive 
and bodily discomfort early in the disease course may be particularly relevant to patients, especially while 
they still may be engaged in activities such as work and caregiving/family responsibilities.  Indeed, recent 
work has revealed that in early PD, the non-motor features of the disease seem to be more strongly related 
to HRQOL than motor dysfunction
19
.  Later on in disease, interventions can be extended to incorporate 
other aspects of quality of life as well, for example including communication and adaptive strategies for 
improving ADL performance. Furthermore, identifying correlates of positive HRQOL and psychosocial 
outcomes in PD could help identify those factors, such as coping strategies, that might improve the day to 
day experience of living with PD
20
. 
Limitations of this study includes the cross sectional nature of our data. Another limitation is the 
low sample sizes in the later stages of the disease (especially in the 11+ years disease duration group). 
While the non-parametric techniques utilized in this study are robust to deviations in sample size and 
10 
 
normality, the conservative nature of the techniques employed and smaller sample sizes at more advanced 
disease durations should be considered when interpreting results. Given limitations within the available 
data, clinical variables such as more precise disease severity could not be explored or controlled for.  
Disease duration was also retrospectively rated by patients, and this may introduce bias in the rating.  
Disease duration data was collected categorically rather than in free response, precluding more advanced 
statistical analysis. 
In summary, our results indicate that disease duration has a differential effect on the various 
domains of health related quality of life. Some of these domains, like cognition and bodily comfort are 
impacted earlier in disease progression and appear similar when comparing groups in the first decade of 
the disease, while other areas are lower about 6-10 years in the disease relative to those early in the 
disease course. Future studies assessing quality of life predictors may want to consider domain-specific 
effect of disease duration. Further assessment of progression related quality of life changes may lead to 
more effective targeting of interventions. 
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Tables [Tables 1 and 2 are uploaded as separate files] 
Figures [Figure 1 is uploaded as a separate file] 
  
Table 1: Demographic and Clinical Variables for the Sample 
Variable 0-5 Years   6-10 Years   11+ Years   Total Sample  
 % N % N % N % 
Male Gender 50.21 122 63.41 26 55.56 10 52.32 
Age         
<50 3.29 8 0.00 0 0.00 0 2.65 
51-60 10.29 25 19.51 8 5.56 1 11.26 
61-70 32.51 79 36.59 15 38.39 7 33.44 
71-80 34.57 84 24.39 10 38.89 7 33.44 
81+ 19.35 47 19.51 8 16.67 3 19.21 
H&Y        
1 25.00 58 21.95 9 0.00 0 23.10 
2 71.98 167 63.41 26 64.71 11 70.34 
3 3.02 7 4.88 2 17.65 3 4.14 
4 0.00 0 7.32 3 11.76 2 1.72 
5 
Self-Reported: 
Depression 
Anxiety 
Cognitive Difficulties 
0.00 
 
29.10 
34.02 
46.31 
0 
 
71 
83 
113 
2.44 
 
34.15 
39.02 
46.34 
1 
 
14 
16 
19 
5.88 
 
50.0 
33.33 
46.34 
1 
 
9 
6 
9 
0.69 
 
31.02 
34.65 
50.00 
 
Table 1
  
Note: H&Y  - Hoehn & Yahr ratings 
  
Table 2: PDQ-39 Subscales across 3 levels of disease duration 
Subscale (A) 0-5 Years (B) 6-10 Years (C) 11+ Years Post-Hoc 
 Mean SD Mean SD Mean SD  
Total 23.47 14.95 33.08 17.70 46.02 19.75 A<B<C 
Mobility 32.18 28.19 45.85 26.72 64.17 33.31 A< (B=C) 
Activities of Daily 
Living 
22.81 22.09 38.92 27.76 56.48 32.78 A<(B=C) 
Emotional Well 
Being 
25.40 20.58 34.25 23.19 45.60 22.84 A<(B=C) 
Stigma 13.32 17.94 27.74 22.62 37.15 27.16 A<(B=C) 
Social Support 8.54 14.30 14.43 21.97 21.30 22.73 ns 
Cognition 28.66 19.45 32.47 23.06 47.22 18.96 (A=B)<C 
Communication 19.43 17.62 31.30 21.23 40.74 24.07 A<(B=C) 
Bodily Discomfort 37.36 21.55 39.63 26.40 55.55 20.61 (A=B)<C 
 
Note: Dunn’s test for significant omnibus tests were employed as a post-hoc analysis; ns = not significant 
 
Table 2
  
Table 3: Hierarchical Multiple Regression Analyses Predicting PDQ Subscales from PD Severity, Self-Reported 
Neuropsychiatric Variables, and Disease Duration 
 
PDQ-39 Domain 
 Mobility Activities of 
Daily 
Living 
Emotional 
Well-Being 
Stigma Social 
Support 
Cognition Communication Bodily 
Discomfort 
Predictor ΔR2 Β ΔR2 Β ΔR2 Β ΔR2 Β ΔR2 Β ΔR2 Β ΔR2 Β ΔR2 Β 
Step 1: H&Y, 
Depression, 
Anxiety, 
Cognitive 
Problems 
.14*  .17*  .40*  .13*  .11*  .29*  .23*  .09*  
                 
Step 2: PD 
Duration 
.04* .23 .08* .31 .03* .18 .07* .28 .02 .14 .03* .17 .06* .27 .02 .15 
                 
Total R2 .18*  .25*  .43*  .21*  .14*  .31*  .29*  .11*  
 
Notes: * p<.006; 
Table 3
  
Figure 1: Select PDQ-39 Subscale Scores by PD Duration Groups 
 
Figure
